CellSource Co Ltd
TSE:4880
Intrinsic Value
CellSource Co., Ltd. engages in regenerative medicine related business. [ Read More ]
The intrinsic value of one CellSource Co Ltd stock under the Base Case scenario is 1 246.36 JPY. Compared to the current market price of 1 522 JPY, CellSource Co Ltd is Overvalued by 18%.
Valuation Backtest
CellSource Co Ltd
Run backtest to discover the historical profit from buying and selling CellSource Co Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
CellSource Co Ltd
Current Assets | 5.4B |
Cash & Short-Term Investments | 4.7B |
Receivables | 321.5m |
Other Current Assets | 388.1m |
Non-Current Assets | 1.4B |
PP&E | 793.1m |
Intangibles | 42.7m |
Other Non-Current Assets | 583.4m |
Current Liabilities | 626.2m |
Accounts Payable | 83.8m |
Accrued Liabilities | 31.5m |
Other Current Liabilities | 510.9m |
Non-Current Liabilities | 220.5m |
Other Non-Current Liabilities | 220.5m |
Earnings Waterfall
CellSource Co Ltd
Revenue
|
4.6B
JPY
|
Cost of Revenue
|
-1.5B
JPY
|
Gross Profit
|
3.2B
JPY
|
Operating Expenses
|
-2.1B
JPY
|
Operating Income
|
1.1B
JPY
|
Other Expenses
|
-225.1m
JPY
|
Net Income
|
851m
JPY
|
Free Cash Flow Analysis
CellSource Co Ltd
Profitability Score
Profitability Due Diligence
CellSource Co Ltd's profitability score is 76/100. The higher the profitability score, the more profitable the company is.
Score
CellSource Co Ltd's profitability score is 76/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
CellSource Co Ltd's solvency score is 93/100. The higher the solvency score, the more solvent the company is.
Score
CellSource Co Ltd's solvency score is 93/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
CellSource Co Ltd
According to Wall Street analysts, the average 1-year price target for CellSource Co Ltd is 1 836 JPY with a low forecast of 1 818 JPY and a high forecast of 1 890 JPY.
Shareholder Return
Price
CellSource Co Ltd
Average Annual Return | 191.12% |
Standard Deviation of Annual Returns | 401.42% |
Max Drawdown | -95% |
Market Capitalization | 30.1B JPY |
Shares Outstanding | 19 899 896 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
CellSource Co., Ltd. engages in regenerative medicine related business. The company is headquartered in Shibuya-Ku, Tokyo-To and currently employs 90 full-time employees. The company went IPO on 2019-10-28. The firm operates in two business segments. The Regenerative Medicine Related business segment is engaged in the provision of contracted services for processing tissues and cells derived from fat and blood to medical institutions, and support services for regenerative medicine laws and regulations related to safety assurance such as regenerative medicine, as well as sales of medical equipment. The Consumer business segment is engaged in the sales of cosmetics and facial products to general consumers.
Contact
IPO
Employees
Officers
The intrinsic value of one CellSource Co Ltd stock under the Base Case scenario is 1 246.36 JPY.
Compared to the current market price of 1 522 JPY, CellSource Co Ltd is Overvalued by 18%.